Pfizer to stop selling Premarin hormone therapy in Canada

The disclosure offers no rationale, which leaves the market to interpret a product exit without guidance from the manufacturer — a notable gap for clinicians and patients who rely on an established branded menopause therapy. The effect is concentrated in Canada, where the removal narrows the branded hormone-replacement options available rather than signaling anything about Pfizer's wider portfolio. Whether the withdrawal reflects commercial calculus or supply considerations, and how Canadian prescribers adjust, are the open questions worth watching.